NeuroVision receives funding to develop dementia blood test

2021 08 24 22 29 3700 Woman Senior Citizen 400

NeuroVision Imaging has received funding from the Alzheimer's Drug Discovery Foundation (ADDF) to speed up the development of a novel blood-based lab test to predict dementia before the clinical onset of disease.

The Sacramento, CA-based company will develop an "ultramultiplex assay" to measure multiple blood biomarkers that are associated with the development of dementia, it said. Additionally, the project will further NeuroVision's work on a proprietary blood assay that appears to mirror beta-amyloid protein load in the brain, the company noted.

The company believes that the ability to measure multiple dementia-related biomarkers in the blood and correlate them with disease status and prognosis could make diagnostic testing more practical, less invasive, and less costly.

Spinal fluid tests may aid PET scans of Alzheimer's disease
2022 03 02 20 27 6315 2022 03 04 Tau Biomarkers 400
Page 1 of 2
Next Page